Department of Protein Science, KTH Royal Institute of Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), AlbaNova University Centre, Stockholm, Sweden.
Methods Mol Biol. 2021;2178:245-249. doi: 10.1007/978-1-0716-0775-6_17.
Therapeutic antibodies are at the forefront of modern medicine where high purity, which is typically obtained by Protein A-based affinity purification, is of utmost importance. In this chapter, we present a method for neutral and selective purification of antibodies by utilizing an engineered affinity ligand, Z, derived from Protein A. This domain displays a calcium-dependent binding of antibodies and has been multimerized and immobilized to a chromatography resin to achieve an affinity matrix with high binding capacity. IgG antibodies can be eluted from the tetrameric Z ligand at pH 7 with the addition of EDTA, or at pH 5.5 with EDTA for purification of monoclonal IgG1, which is significantly milder than the low pH (3-4) required in conventional Protein A affinity chromatography. Here, a protocol for selective capture of IgG with elution at neutral pH from a Z tetramer ligand immobilized on a chromatography resin is described.
治疗性抗体是现代医学的前沿领域,其中高纯度至关重要,通常通过基于蛋白 A 的亲和纯化来获得。在本章中,我们介绍了一种利用工程化的亲和配体 Z 来实现抗体的中性和选择性纯化的方法。该结构域表现出对抗体的钙离子依赖性结合,并已被多聚化并固定在色谱树脂上,以实现具有高结合容量的亲和基质。IgG 抗体可以在 pH 7 时加入 EDTA 从四聚体 Z 配体中洗脱,或者在 pH 5.5 时加入 EDTA 用于单克隆 IgG1 的纯化,这比传统的蛋白 A 亲和层析所需的低 pH(3-4)要温和得多。此处描述了一种从固定在色谱树脂上的 Z 四聚体配体中以中性 pH 洗脱 IgG 的选择性捕获方案。